Basel‑based Roche used its annual Pharma Day to reaffirm a market‑leading stance for its drug pipeline. Chief Executive Teresa Graham emphasized a "rich" pipeline of potential blockbusters and noted that after a dip in 2022 caused by research setbacks and patent expiries, the company has returned to growth through an ambitious development program.
Since the previous Pharma Day, Roche reports that ten regulatory‑relevant studies met their targets and six programs have entered the approval‑relevant phase, with three more moving into Phase II. The firm now targets up to 20 new compounds that could reach market by 2030. Among them, the breast‑cancer candidate Giredestrant is projected to generate more than 30 billion Swiss francs in peak sales.
In late 2023 Roche introduced "The Bar," a new evaluation framework that raises the threshold for advancing drug candidates. According to chief medical officer Levi Garraway, the stricter criteria have reduced the total number of projects while lifting the overall value of the remaining portfolio. The company cites a 65% success rate for projects reaching Phase III in 2025 and a rate exceeding 80% in 2026, alongside shorter development timelines and cost savings.
Artificial intelligence is positioned as a cross‑cutting tool in Roche’s research strategy. The company plans to embed AI from disease understanding through target discovery to candidate optimisation. Genentech’s research head Aviv Regev presented a "Lab‑in‑the‑Loop" approach, where AI models analyse large biological and chemical datasets, generate predictions, and feed experimental results back into the models. While AI is expected to boost confidence in early‑stage decisions, Roche cautions that human‑run clinical trials remain indispensable.
Overall, Roche’s Pharma Day signalled a commitment to accelerate its pipeline, leverage AI for efficiency, and pursue high‑value drug launches that could reshape its revenue profile over the next decade.